Journal
CARDIOVASCULAR RESEARCH
Volume 74, Issue 2, Pages 223-234Publisher
OXFORD UNIV PRESS
DOI: 10.1016/j.cardiores.2007.02.012
Keywords
transforming growth factor-beta 1; intimal thickening; percutaneous coronary intervention; vascular smooth muscle cell; extracellular matrix; transforming growth factor beta 3; tranilast
Categories
Ask authors/readers for more resources
Intimal thickening is the most important cause of in-stent restenosis. The pathology of intimal thickening is attributable to a local inflammatory response after vascular injury which results in the production of cytokines. Transforming growth factor-beta 1 (TGF-beta 1) is a profibrotic cytokine that is involved in the induction of intimal thickening. Up-regulation of TGF-beta 1 after arterial injury results in the activation of various downstream pathways which stimulate the proliferation and migration of vascular smooth muscle cells, as well as the production of local extracellular matrix proteins. Recent evidence suggests that antagonizing TGF-beta 1 activity with direct or indirect inhibitors may attenuate or prevent intimal thickening. Additionally, TGF-beta 1 synthesis, activation and downstream regulation may also serve as significant sources of treatment. This review attempts to show the role of TGF-beta 1 in the pathology of intimal thickening and underlines the importance of TGF-beta 1 as a target for therapy. (c) 2007 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available